Indonesia’s pharma sector to rely on imports despite export boost: report

Imports are forecast to hit $1.6b by 2029, whilst exports are expected to reach $927m.

Indonesia’s pharmaceutical sector is expected to remain reliant on imports despite efforts to boost exports by expanding domestic production, according to BMI.

Pharmaceutical Imports are anticipated to rise to $1.6b by 2029, whilst exports are expected to reach $927m.

The country’s limited capacity for manufacturing pharmaceutical raw materials has prompted investment in new facilities that will primarily cater to domestic demand.

However, reliance on imports is expected to persist, as recent investments in research and development will likely take years to translate into sufficient local production capacity to meet demand.

“Medicine imports will continue to dominate the market, with an ongoing trade deficit despite increasing domestic production,” the report said.